Presidio actively evaluates in-licensing opportunities for programs and compounds of all development stages, with a preference for orally bioavailable, small molcule inhibitors for HCV.
Presidio is also open to selective out-licensing and partnership discussions for our current programs.
If you are interested in business development and partnering opportunities with Presidio, please contact:
Omar K. Haffar, PhD
Chairman of the Board